NYSE:LCI - Lannett Stock Price, News, & Analysis

Get Started

$5.41 -0.03 (-0.55 %)

(As of 11/14/2018 04:00 PM ET)

Previous Close$5.44

Today's Range$5.08 - $5.54

52-Week Range$3.33 - $30.35

Volume1.34 million shs

Average Volume1.72 million shs

Market Capitalization$215.02 million

P/E Ratio1.75

Dividend YieldN/A

Beta2.01

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages. It also provides its products for various medical indications comprising cholesterol, muscle spasm, pain management, irritable bowel, antipsychosis, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, migraine, bronchospasms, and gallstone. In addition, the company manufactures active pharmaceutical ingredients. It markets its products under the Lipitor, Lioresal, Bentyl, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Concerta, Toprol-XL, Prilosec, Ditropan, Protonix, Imitrex, Brethine, and Actigall brands to generic pharmaceutical and private label distributors, drug wholesalers, chain drug retailers, mail-order pharmacies, other pharmaceutical manufacturers, managed care and health maintenance organizations, hospital buying groups, and governmental entities. The company has supply and development agreements with Jerome Stevens Pharmaceuticals, Summit Bioscience LLC, HEC Pharm Group, Andor Pharmaceuticals LLC, Dexcel Pharma, and Aralez Pharmaceuticals. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Receive LCI News and Ratings via Email

Sign-up to receive the latest news and ratings for LCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:LCI

Previous Symbol

CUSIP51601210

Webwww.lannett.com

Phone215-333-9000

Debt

Debt-to-Equity Ratio2.44

Current Ratio2.87

Quick Ratio2.07

Price-To-Earnings

Trailing P/E Ratio1.75

Forward P/E Ratio2.55

P/E GrowthN/A

Sales & Book Value

Annual Sales$684.56 million

Price / Sales0.31

Cash Flow$4.4711 per share

Price / Cash1.21

Book Value$8.01 per share

Price / Book0.68

Profitability

EPS (Most Recent Fiscal Year)$3.10

Net Income$28.69 million

Net Margins-39.74%

Return on Equity21.32%

Return on Assets7.39%

Miscellaneous

Employees1,251

Outstanding Shares38,950,000

Market Cap$215.02 million

OptionableOptionable

Lannett (NYSE:LCI) Frequently Asked Questions

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) announced its quarterly earnings data on Wednesday, November, 7th. The company reported $0.44 EPS for the quarter, beating the Zacks' consensus estimate of $0.39 by $0.05. The firm earned $155.10 million during the quarter, compared to the consensus estimate of $145.79 million. Lannett had a negative net margin of 39.74% and a positive return on equity of 21.32%. The firm's revenue was up .1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 earnings per share. View Lannett's Earnings History.

When is Lannett's next earnings date?

Lannett is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Lannett.

What price target have analysts set for LCI?

6 brokers have issued 12 month price targets for Lannett's stock. Their forecasts range from $8.00 to $43.00. On average, they anticipate Lannett's stock price to reach $24.8750 in the next twelve months. This suggests a possible upside of 359.8% from the stock's current price. View Analyst Price Targets for Lannett.

What is the consensus analysts' recommendation for Lannett?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lannett.

Has Lannett been receiving favorable news coverage?

Media coverage about LCI stock has trended positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lannett earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Lannett's key competitors?

Some companies that are related to Lannett include Aptinyx (APTX), Akorn (AKRX), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA), Viking Therapeutics (VKTX), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Deciphera Pharmaceuticals (DCPH), Athenex (ATNX), Clovis Oncology (CLVS), Dynavax Technologies (DVAX), Eagle Pharmaceuticals (EGRX), Homology Medicines (FIXX) and Cara Therapeutics (CARA).

Who are Lannett's key executives?

Lannett's management team includes the folowing people:

Mr. Timothy C. Crew, CEO & Director (Age 57)
Mr. Martin P. Galvan, VP of Fin. & CFO (Age 66)
Mr. Samuel H. Israel, VP, Gen. Counsel & Chief Legal Officer (Age 56)
Mr. John M. Abt, VP & Chief Quality Operations Officer (Age 53)
Mr. John Kozlowski, Chief of Staff & Strategy Officer (Age 46)

Who are Lannett's major shareholders?

Lannett's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.17%), LSV Asset Management (5.33%), JPMorgan Chase & Co. (1.76%), JPMorgan Chase & Co. (1.76%), Bank of New York Mellon Corp (1.70%) and Canada Pension Plan Investment Board (1.38%). Company insiders that own Lannett stock include Arthur P Bedrosian, David Farber, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett.

Which institutional investors are selling Lannett stock?

LCI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Connor Clark & Lunn Investment Management Ltd., LSV Asset Management and Credit Suisse AG. Company insiders that have sold Lannett company stock in the last year include Arthur P Bedrosian, David Farber and Kevin Smith. View Insider Buying and Selling for Lannett.

Which institutional investors are buying Lannett stock?

LCI stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Canada Pension Plan Investment Board, SG Americas Securities LLC, X Square Capital LLC, Trexquant Investment LP, Adams Diversified Equity Fund Inc. and NJ State Employees Deferred Compensation Plan. Company insiders that have bought Lannett stock in the last two years include Arthur P Bedrosian, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.

How do I buy shares of Lannett?

Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $5.41.

How big of a company is Lannett?

Lannett has a market capitalization of $215.02 million and generates $684.56 million in revenue each year. The company earns $28.69 million in net income (profit) each year or $3.10 on an earnings per share basis. Lannett employs 1,251 workers across the globe.

What is Lannett's official website?

The official website for Lannett is http://www.lannett.com.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000.

MarketBeat Community Rating for Lannett (NYSE LCI)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		394 (Vote Outperform)
Underperform Votes:		311 (Vote Underperform)
Total Votes:		705

MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 11/14/2018 by MarketBeat.com Staff

Featured Article: What is the NASDAQ Stock Market?